Trimetazidine hydrochloride sustained release tablet and preparation method thereof

Abstract

The invention discloses a trimetazidine hydrochloride sustained release tablet prepared from the following ingredients in percentage by weight: 10-25% of trimetazidine hydrochloride, 20-60% of hydrophilic gel skeleton material, 1-20% of a hydrophobic blocker, 15-55% of filler, 1-10% of a lubricant, 0 or 1-10% of a coating material and a proper dosage of adhesive. A wet granulation method is adopted in the preparation process. After the trimetazidine hydrochloride sustained release tablet disclosed by the invention touches water, the hydrophilic gel skeleton material can expand rapidly to form a gel layer with a plurality of pores, a drug can be slowly released through the pores, and the hydrophobic blocker can partially block the pores to avoid the burst release of the drug. Proper mass and proper proportion of hydrophilic gel skeleton material and hydrophobic blocker are added to realize slow and uniform release of the drug under the cooperation of the two ingredients and well avoid the burst release phenomenon so as to beneficially ensure the safety and effectiveness of drug therapy.

Description

technical field [0001] The invention belongs to the field of pharmaceutical preparations, and in particular relates to a trimetazidine hydrochloride sustained-release tablet and a preparation method thereof. Background technique [0002] Angina pectoris is a common cardiovascular disease, which is caused by coronary artery atherosclerosis and stenosis, coronary artery insufficiency, temporary myocardial ischemia and hypoxia, and a group of comprehensive symptoms with precordial pain as the main clinical manifestation. It is a kind of coronary heart disease with the highest incidence rate, which seriously threatens the health and life of human beings. It is mainly divided into stable angina and unstable angina. Angina pectoris can occur at any time in 24 hours, but most of them are from early morning to morning, and variant angina pectoris often occurs regularly at night. Therefore, it is required that the therapeutic drug can maintain an effective therapeutic concentration...

AI Technical Summary

Problems solved by technology

[0003] At present, the drugs for treating angina pectoris are mainly concentrated in nitrates, adrenergic β-receptor blockers and calcium channel antagonists, but they all exert myocardial protection through indirect effects such as improving the balance of oxygen supply and demand in the ischemic myocardium. And can only relieve the symptoms of angina pectoris

Most patients with angina have congestive heart insufficiency, chronic lung disease, or diabetes, and the effects of these drugs can further damage an already weakened heart

Therefore, its curative effect and clinical application are limited

Images